Infinity Pharmaceuticals, Inc.

Stock Symbol: 
Case Status: 

Ademi LLP is investigating Infinity (NASDAQ: INFI) for possible breaches of fiduciary duty and other violations of law in its transaction with MEI Pharma.

Ademi LLP alleges Infinity’s financial outlook and prospects are excellent and yet Infinity shareholders are expected to own approximately only 42% of the outstanding equity of the combined company immediately following the merger. The transaction agreement unreasonably limits competing bids for Infinity by imposing a significant penalty if Infinity accepts a superior bid. Infinity insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Infinity’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Infinity.